These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. The era of immuno-oncology: are we there yet? Villasboas JC; Ansell SM Oncology (Williston Park); 2015 Mar; 29(3):204-5. PubMed ID: 25772457 [No Abstract] [Full Text] [Related]
7. Optimal use of bendamustine in chronic lymphocytic leukemia, non-Hodgkin lymphomas, and multiple myeloma: treatment recommendations from an international consensus panel. Cheson BD; Wendtner CM; Pieper A; Dreyling M; Friedberg J; Hoelzer D; Moreau P; Gribben J; Knop S; Montillo M; Rummel M Clin Lymphoma Myeloma Leuk; 2010 Feb; 10(1):21-7. PubMed ID: 20223726 [TBL] [Abstract][Full Text] [Related]
8. Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-Hodgkin lymphoma. Dennie TW; Kolesar JM Clin Ther; 2009; 31 Pt 2():2290-311. PubMed ID: 20110042 [TBL] [Abstract][Full Text] [Related]
9. Veltuzumab, an anti-CD20 mAb for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and immune thrombocytopenic purpura. Milani C; Castillo J Curr Opin Mol Ther; 2009 Apr; 11(2):200-7. PubMed ID: 19330725 [TBL] [Abstract][Full Text] [Related]
10. PI3K signaling pathway in normal B cells and indolent B-cell malignancies. Pongas G; Cheson BD Semin Oncol; 2016 Dec; 43(6):647-654. PubMed ID: 28061982 [TBL] [Abstract][Full Text] [Related]
11. [Increased response rate with rituximab in relapsed and refractory follicular and mantle cell lymphomas -- results of a prospective randomized study of the German Low-Grade Lymphoma Study Group]. Forstpointner R; Hänel A; Repp R; Hermann S; Metzner B; Pott C; Hartmann F; Rothmann F; Böck HP; Wandt H; Unterhalt M; Hiddemann W Dtsch Med Wochenschr; 2002 Oct; 127(43):2253-8. PubMed ID: 12397539 [TBL] [Abstract][Full Text] [Related]
12. Applications of monoclonal antibodies for the treatment of hematological malignancies. Migkou M; Dimopoulos MA; Gavriatopoulou M; Terpos E Expert Opin Biol Ther; 2009 Feb; 9(2):207-20. PubMed ID: 19236251 [TBL] [Abstract][Full Text] [Related]
13. [Fludarabine in the treatment of chronic lymphocytic leukemia and other lymphoproliferative disorders]. Pawelski S Acta Haematol Pol; 1995; 26(3):263-8. PubMed ID: 8525771 [TBL] [Abstract][Full Text] [Related]
14. [Clinical use of monoclonal antibodies in malignant lymphomas]. Schnell R; Hiddemann W; Diehl V; Engert A Internist (Berl); 2001 Jun; 42(6):815-6, 819-26. PubMed ID: 11449628 [No Abstract] [Full Text] [Related]
15. Monoclonal antibodies for the treatment of hematologic malignancies: clinical trials in Japan. Tobinai K Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S90-6. PubMed ID: 12819934 [TBL] [Abstract][Full Text] [Related]
16. CMC-544 (inotuzumab ozogamicin) shows less effect on multidrug resistant cells: analyses in cell lines and cells from patients with B-cell chronic lymphocytic leukaemia and lymphoma. Takeshita A; Shinjo K; Yamakage N; Ono T; Hirano I; Matsui H; Shigeno K; Nakamura S; Tobita T; Maekawa M; Ohnishi K; Sugimoto Y; Kiyoi H; Naoe T; Ohno R Br J Haematol; 2009 Jun; 146(1):34-43. PubMed ID: 19388933 [TBL] [Abstract][Full Text] [Related]
17. Bendamustine produces durable responses with an acceptable safety profile in patients with rituximab-refractory indolent non-Hodgkin lymphoma. Cheson BD; Friedberg JW; Kahl BS; Van der Jagt RH; Tremmel L Clin Lymphoma Myeloma Leuk; 2010 Dec; 10(6):452-7. PubMed ID: 21189660 [TBL] [Abstract][Full Text] [Related]